Jazz Pharmaceuticals (JAZZ) FY2020 results: revenue $2.4 billion, up 9.3% on the year
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $2.4 billion for fiscal 2020, the year ended 31 December 2020, up 9.3% on the year before. Net income was $239 million, down 54.4%, and diluted earnings per share $4.22. The figures are the company's own, from the 10-K it filed with the SEC on 23 February 2021.
Revenue
$2.4 billion
+9.3% on the year
FY2013FY2020
Operating margin
16.0%
24.6% a year earlier
FY2013FY2020
Net income
$239 million
-54.4% on the year
FY2013FY2020
Diluted EPS
$4.22
-53.6% on the year
FY2013FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
2,364
2,162
1,891
+9.3%
Research and development
335
300
227
+11.9%
Selling, general and administrative
854
737
684
+15.9%
Operating income
378
532
615
-29.0%
Operating margin
16.0%
24.6%
32.5%
Interest expense
87.6
62.5
56.7
+40.2%
Pre-tax income
275
454
529
-39.4%
Income tax
33.5
-73.2
80.2
Effective tax rate
12.2%
-16.1%
15.1%
Net income
239
523
447
-54.4%
Net margin
10.1%
24.2%
23.6%
Diluted EPS
$4.22
$9.09
$7.30
-53.6%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
900
776
799
+15.9%
Capital expenditure
15.0
40.1
20.4
-62.6%
Free cash flow
885
736
779
+20.2%
Free cash flow margin
37.4%
34.1%
41.2%
Cash from investing
-1,008
-155
-394
Cash from financing
528
-294
-479
Depreciation and amortisation
18.7
15.3
15.2
+22.2%
Share-based compensation
121
111
102
+9.4%
Buybacks
147
301
524
-51.4%
Diluted shares, weighted
57m
58m
61m
-1.8%
Shares outstanding at period end
56m
56m
58m
+0.1%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
3,660
3,111
2,757
+17.6%
Debt
2,095
1,607
1,596
+30.3%
Operating lease liabilities
140
151
0.0
-7.4%
Finance lease liabilities
0.0
n/a
n/a
Other liabilities
641
669
850
-4.2%
Total liabilities and equity
6,536
5,539
5,203
+18.0%
Fixed assets
128
132
200
-2.7%
Goodwill
958
920
928
+4.2%
Intangible assets
2,195
2,441
2,731
-10.1%
Securities held for sale or to maturity
2,133
1,077
825
+98.0%
Cash and equivalents
1,058
637
310
+66.0%
Receivables
396
356
264
+11.4%
Inventory
95.4
78.6
53.0
+21.4%
Total assets
6,536
5,539
5,203
+18.0%
10-K for the year ended 31 December 2020, filed 23 February 2021: the filing.